PDF Cover

Recombinant Vaccines Market

The market for Recombinant Vaccines was estimated at $19.7 billion in 2025; it is anticipated to increase to $33.9 billion by 2030, with projections indicating growth to around $58.1 billion by 2035.

Report ID:DS1804002
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Biotechnology
Recombinant Vaccines
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Recombinant Vaccines Market Outlook

Revenue, 2025

$19.7B

Forecast, 2035

$58.1B

CAGR, 2026 - 2035

11.4%

The Recombinant Vaccines industry revenue is expected to be around $19.7 billion in 2026 and expected to showcase growth with 11.4% CAGR between 2026 and 2035. The growing global recombinant vaccine market is reflective of the important role these vaccines have taken on in the global immunisation scene, driven by factors such as a rising awareness of preventable diseases, national immunisation programs and investment in biotechnology. Preventative vaccines for Hepatitis B and human papillomavirus made up 62.6% of revenue from vaccines given for specific conditions. This underlines how significant demand for vaccines that stop common viral diseases helps to maintain and expand the market. In terms of technology, subunit protein vaccines make up the majority of the recombinant vaccines market with earnings of around $8.53 billion in 2025, largely because they have a safer profile compared to other vaccines, are easy to manufacture and are used to immunise both adults and children. The prospects for recombinant technologies have been enhanced by several factors including advances in pipeline, mRNA technology and DNA vaccines, increasing healthcare expenditure and the need for pandemic preparedness. There are also strategic alliances.

These vaccines are produced in a bioreactor with a specially adapted virus which causes the host cell to produce the viral coat proteins. These coat proteins are then used to stimulate the immune system in the same way as the original pathogen would. The recombinant virus used is generally not only capable of causing disease. Several advantages of the subunit vaccines include a reduced risk of adverse reactions compared to the live or killed virus vaccines, precise targeting of the antigen, the possibility of combining the vaccine with adjuvants and the potential to use them in a vaccine with other vaccines. The companys products are used for several major applications, including Hepatitis B and HPV vaccines, vaccines for respiratory and meningococcal disease and travel related vaccinations. Furthermore, several oncology and viral infection treatments are being trialled. Recombinant vaccines are seeing an increase in demand due to factors such as a rising focus on immunizing adults and pregnant women, development of vaccine production platforms for rapidly emerging diseases, new uses for protein subunit vaccines, and a focus on equal access to vaccines for low and middle income countries. The recombinant vaccines sector plays a dynamic role within the worlds disease prevention and control systems, and is highly responsive to changing global needs.

Recombinant Vaccines market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Recombinant Vaccines Market Outlook

Market Key Insights

  • By 2035 the industry for recombinant vaccines is estimated to reach $58.1 billion and $19.7 billion in 2025. The sector has achieved a compound annual growth rate of 11.4% in demand which stems from the increasing needs in the fields of immunisation programmes, cancer treatment and veterinary work.

  • The pharmaceutical giants Merck & Co., GlaxoSmithKline and Pfizer Inc. are all influential in their sector and have a significant impact on the competitive market landscape.

  • The Recombinant Vaccines market will be led by the U.S. and Germany through the period to 2030. This duo are expected to grow at a compound annual growth rate of 8.3% to 12.0% between 2025 and 2030.

  • The highest growth rates, ranging between 10.9% and 14.3% , are expected in emerging markets like Brazil, India and Mexico.

  • DNA vaccine technology is poised to give a boost to the recombinant vaccines market. By 2030, this shift is expected to increase the recombinant vaccine market size by $3 billion.

  • Between 2025 and 2035, the recombinant vaccine industry is expected to see a $38.4 billion increase. As such, manufacturers are focusing their efforts on key segments within the market to gain a greater share.

  • The recombinant vaccines industry is likely to grow to a significant degree due to advances in the technology involved in vaccine production and the growing prevalence of infectious diseases. By 2035, the market for these vaccines should be 194% bigger than it was in 2025.

recombinant vaccines market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Recombinant Vaccines - Country Share Analysis

Opportunities in the Recombinant Vaccines

The largest market for recombinant vaccines as of protein subunit technology is also currently that of 8.53 billion USD. By the year 2030, this figure is expected to reach 12.65 billion USD. Growing elderly populations in Europe coupled with programmes for adult influenza immunisation driven by employers are pushing for improved, safer flu, RSV and shingles vaccines. There is considerable potential for new vaccines that combine protein subunits and virus like particles and are targeted towards adults with multiple health conditions. Across Western and Central Europe the growth of protein subunit vaccines will be driven by partnerships between primary care networks, payers and vaccine manufacturers.

Growth Opportunities in North America and Asia-Pacific

The market for recombinant vaccines in North America is being driven by strong public inoculation programmes and a well established system of reimbursement. Furthermore, the region has a high level of awareness about cervical cancer, which is HPV related. This is followed by shingles and seasonal flu vaccines. Key region's for growth will be in lifecycle management and expansion of vaccine labels for HPV and shingles vaccines, in particular the development of adult and booster doses, and the incorporation of new adjuvants to extend protection against new vaccines. The originator companies along with latter day pipeline monitor entrants using cutting edge recombinant vaccine technology face a highly competitive market situation. Due to their well established biologics manufacturing facilities and comprehensive clinical trials networks, they can introduce vaccines which cover various age groups and indications quickly. The companys strategy should be on creating and selling high quality products that provide effective health benefits. This can be done by gathering data on how these products work in real life. Also it should concentrate on how patients stick to their prescribed treatments, so that the company can strengthen its negotiating power with those who pay for the treatments and stay competitive despite rising scrutiny of medicine prices.
The regions Recombinant Vaccines market is driven by the expanding middle class, who are now more likely to spend on healthcare, the rapid growth of cities and the governments expansion of vaccination schedules. In tropical countries the demand for dengue vaccine is high and in densely populated countries hepatitis B vaccines remain in demand. Key region's for growth include developing cost effective dengue and hepatitis B vaccines by adopting tiered pricing models and partnering with local companies for the final production and packaging of the vaccines. This will assist in expanding vaccine distribution to poorer regions, and also in maintaining revenue growth driven by increased vaccine sales volume. The vaccine market is comprised of regional companies which are quick to react and major multinationals working on transferring technology and developing recombinant vaccines similar to biosimulans, particularly in markets focusing on low cost solutions. Priorities for strategic development should focus on a number of things including localised clinical data, partnerships between companies and the public sector to secure investment through government funded schemes, and the targeted development of manufacturing capabilities for biologic drugs to make recombinant vaccines a core element of disease prevention in the region.

Market Dynamics and Supply Chain

01

Driver: Rising infectious disease burden and precision-driven vaccine engineering innovations

The recombinant vaccines market is also strongly driven by the increasing incidence of emerging and re-emerging infectious diseases and rapid progress in precision vaccine engineering. Globally, rising zoonotic spillovers, antimicrobial resistance, and mutation-driven viral outbreaks are also pushing governments and health agencies to adopt faster, more adaptable vaccine platforms. Recombinant technologies enable targeted antigen expression, improving immunogenicity while reducing adverse reactions compared to traditional vaccines. Parallelly, advancements in genetic sequencing, expression vectors, and cell-line optimization are also shortening development timelines and improving batch consistency. Novel platforms such as recombinant subunit and viral vector vaccines support scalable manufacturing and rapid strain modification, making them attractive for pandemic preparedness programs. These dual growth factors are also reinforcing long-term investments from biopharmaceutical companies and public health institutions, particularly for diseases with high mutation rates and unmet prophylactic needs.
Beyond infectious disease prevention, recombinant vaccines are also gaining traction in therapeutic and chronic disease applications. also advances in antigen design and adjuvant compatibility are also enabling vaccines targeting cancer, autoimmune disorders, and allergies. This shift is also supported by improved understanding of immune modulation and recombinant protein stability, allowing more precise immune responses. As healthcare systems prioritize preventive and long-term disease management solutions, demand for recombinant platforms is also increasing across oncology and specialty immunology pipelines.
02

Restraint: High development costs and complex manufacturing workflows limiting scalable commercialization

Recombinant vaccines face significant cost barriers due to complex upstream development and downstream purification processes. Advanced bioreactors, stringent quality controls, and validation requirements increase capital expenditure. These factors often raise final vaccine prices, limiting adoption in cost-sensitive regions. As a result, manufacturers may prioritize high-income markets, constraining global revenue potential and slowing volume-driven market expansion.
03

Opportunity: Rapid expansion of mRNA recombinant vaccines for pandemic preparedness in high-income healthcare systems worldwide and Adoption of veterinary recombinant vaccines in intensive livestock production and aquaculture industries across Asia-Pacific

The fastest growing platform within recombinant vaccines are mRNA vaccines which are expected to reach globally a figure of 8.05 billion USD by the year 2030 from 3.59 billion USD. In high income countries vaccine production is well suited to pandemic preparedness because of its design that is flexible, rapid manufacturing processes and its efficacy. There is unused potential in variant specific vaccines and broader infectious disease vaccinations. The production of new formulations will cut down the logistical constraints of the cold chain. logistic Collaborations between public health bodies and biotech companies will significantly increase the development of mRNA vaccines. This will be especially true for the treatment of respiratory diseases and new strains of disease.
The region of the Asia Pacific is in need of veterinary Recombinant Vaccines. These are used primarily in intensive cattle, aquaculture, poultry and pig farming. These vaccines are necessary because of higher biosecurity standards in the region. By 2030, DNA plasmid and virus like particle vaccine technologies are forecast to experience rapid growth. DNA plasmid vaccine sales are predicted to rise globally from $2.03 billion to $3.85 billion. Researchers are exploring new options to combat zoonoses that are on the rise because conventional methods are failing. In densely populated region's where livestock is raised, collaborations between big animal health companies and smaller regional firms will help bring DNA vaccines into use quickly.
04

Challenge: Lengthy regulatory approval timelines and evolving compliance requirements across regions

Stringent and evolving regulatory frameworks pose a major restraint for recombinant vaccines. Extensive clinical validation and post-approval surveillance increase time-to-market, delaying revenue realization. Differences in regulatory expectations across regions further complicate global launches. These delays can reduce competitiveness against faster-approved alternatives, impacting demand forecasting and discouraging smaller players from entering the market.

Supply Chain Landscape

1

Vaccine Development R&D

Merck & Co.GlaxoSmithKline plcModerna Inc
2

Recombinant Vaccines Manufacturing

Pfizer Inc.SanofiMerck & Co
3

Cold Chain Logistics

DHL Supply ChainUPS HealthcareFedEx Logistics
4

Immunization Programs

Hospitals & ClinicsPublic Health AgenciesPediatric Vaccination Centers
Recombinant Vaccines - Supply Chain

Use Cases of Recombinant Vaccines in Immunization Programs & Cancer Treatment

Immunization Programs : In efforts to improve health outcomes recombinant vaccines are frequently employed to fight against different contagious illnesses such as Hepatitis B and Human Papillomavirus (HPV). Their exceptional capacity to focus on pathogens in an accurate and effective way has transformed the field of immunization. Major companies like GlaxoSmithKline and Pfizer are pivotal in manufacturing these vaccines for distribution, across the globe.
Cancer Treatment : Recombinant vaccines are being studied more and more as options for treating different types of cancers with their main advantage being the ability to stimulate an immune response targeted specifically at cancerous cells. Encouraging outcomes from trials suggest their effectiveness in activating our bodys defenses against harmful cells with key companies like Bristol Myers Squibband AstraZeneca leading the way, in this field.
Veterinary : Recombinant vaccines are not used for human health but also play a significant role in veterinary medicine by safeguardind livestock from common diseases effectively and safely without the risk of reversionary concerns prevalent in traditional vaccines. The commercial farming sector benefits from these vaccines as they offer a secure and efficient disease control method. Companies like Boehringer Ingelheim and Zoetis are players, in this field.

Recent Developments

A strategic recombinant vaccines market analysis shows accelerated technology adoption and regulatory momentum, with expanded approvals (e.g., novel protein‑based and VLP vaccines) and diversified expression systems driving robust growth and scale‑up of biologics manufacturing. Recent approvals and expanded indications are bolstering uptake in HPV, RSV, and emerging disease segments, reshaping commercial dynamics and investor interest. The key trend is AI‑enhanced antigen design and modular platforms, which shorten development cycles and improve strain adaptation in response to evolving pathogens, enhancing competitive differentiation and pipeline resilience.

August 2025 : Novavax increased its annual revenue guidance on the strength of vaccine supply agreements with partners such as SK Bioscience and Takeda, supported by a $175 M milestone payment linked to U.S. approval of its recombinant protein COVID‑19 vaccine, Nuvaxovid. This reflects commercialization momentum and strategic partnership growth for its recombinant platform.
June 2025  : Bharat Biotech entered a licensing agreement with GSK for the Shigella vaccine developed on the GMMA recombinant platform, taking responsibility for advanced clinical development, regulatory approvals, and large‑scale manufacturing as GSK supports trial design and commercialization planning.
November 2024  : Novavax launched its 2024‑2025 recombinant protein vaccine formulation nationally at pharmacy chains, offering an alternative to mRNA COVID‑19 vaccines for individuals 12 + years and enhancing its recombinant product footprint.

Impact of Industry Transitions on the Recombinant Vaccines Market

As a core segment of the Biotechnology industry, the Recombinant Vaccines market develops in line with broader industry shifts. Over recent years, transitions such as Shift Towards DNA Vaccines and Integration with personalized medicine have redefined priorities across the Biotechnology sector, influencing how the Recombinant Vaccines market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift Towards DNA Vaccines

DNA vaccines are seeing accelerated adoption within the recombinant vaccines sector, fundamentally altering the business model and growth prospects for manufacturers of genetic vaccines. This is because DNA vaccines allow the precise design of antigens, better immune response and consistent safety when compared to conventional vaccines. DNA vaccines can be quickly designed for emerging diseases through direct genetic engineering of the vaccines antigen. This process gives control over how the disease fighting system is triggered and allows for faster production and development. By 2030, the recombinant vaccine market is predicted to receive a $3 billion boost as a result of this technology driven change. Along with mRNA vaccines, this development will further the recombinant vaccines position as a major growth engine and will allow biopharmaceutical companies, who are focusing on preventive healthcare and vaccine innovation, to further differentiate themselves from their competitors.
02

Integration with personalized medicine

Recombinant vaccines are increasingly aligning with personalized and precision medicine frameworks. Advances in genomics and biomarker identification are enabling patient-specific or population-targeted vaccine designs, particularly in oncology and rare diseases. This transition is reshaping collaborations between vaccine developers, diagnostic companies, and data analytics firms. It is also influencing healthcare delivery models, shifting value from volume-based immunization to outcome-driven therapeutic vaccination strategies.